Eli Lilly Strikes Another Genetic Meds Deal, Gaining Global Rights to MeiraGTx Retinal Gene Therapy
Eli Lilly is paying $75 million up front for global rights to AAV-AIPL1, a gene…
Eli Lilly Strikes Another Genetic Meds Deal, Gaining Global Rights to MeiraGTx Retinal Gene Therapy
Eli Lilly is paying $75 million up front for global rights to AAV-AIPL1, a gene therapy on track for U.S. and European regulatory submissions in the rare, inherited eye disorder Leber congenital amaurosis 4, or LCA4. The deal brings to Lilly another late-stage gene therapy for the eyes following the pharma giant’s October acquisition of…
What Can Healthcare Today Learn From Apple Circa 2007? A Lot, Actually.
The future of healthcare isn’t about one company “owning it all.” It’s about building the kind of ecosystem Apple unlocked with the iPhone and its App Store — one that empowers and changes the game for everyone. The post What Can Healthcare Today Learn From Apple Circa 2007? A Lot, Actually. appeared first on MedCity…
The Doctor’s Monopoly Is Dead and We’re All Better For It
Authority built on information control cannot survive in the age of AI and instant access. But authority built on wisdom, judgment, empathy, and genuine partnership? That’s eternal. And it’s exactly what patients have been asking for all along. The post The Doctor’s Monopoly Is Dead and We’re All Better For It appeared first on MedCity…
Shutdown Has Highlighted Washington’s Retreat From Big Ideas on Health Care
In the run-up to the 2020 election, all 20 Democratic presidential candidates promised voters they’d pursue bold changes to health care, such as a government-run insurance plan or expanding Medicare to cover every American. Fast-forward to the congressional stalemate that has closed the federal government for more than a month. Democrats, entrenched on one side…
As Health Companies Get Bigger, So Do the Bills. It’s Unclear if Trump’s Team Will Intervene.
A cancer patient might live in a town with four oncology groups, but only one accepts his insurance — the one owned by his insurer. A young couple could see huge bills after their child is born, because their insurer agreed to the health system’s rates in exchange for a contract with obstetricians across the…
Kai Romero, Evidently
Kai Romero is Head of Clinical Success at Evidently. The company is one of many that are using AI to dive into the EMR and extract data to deliver it to clinicians. It works to get really great information from the EMR to various flavors of clinicians in a fast and innovative way. Kai leads…
How Philips Uses Monitoring Tech to Help Close Care Access Gaps
Philips is using its patient monitoring devices to help health systems deliver care more efficiently, especially in areas with specialist shortages. The company’s connected devices enable continuous monitoring from home to hospital and back, which can reduce diagnostic delays and improve patient safety, said Nick Wilson, Philps’ vice president of product. The post How Philips…
Amae Health Raises $25M to Improve Care for Severe Mental Illness
Amae Health’s Series B round was led by Altos Ventures and included participation from Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC. The post Amae Health Raises $25M to Improve Care for Severe Mental Illness appeared first on MedCity News.
Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera
Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favor, ending a bidding war for Metsera and its next-generation obesity…
Understanding Various Measures to Assess Hospital Finances: A Cheat Sheet
This one-page fact sheet provides basic information for understanding measures of hospital finances. It describes profits margins and other common measures of hospitals’ financial well-being, as well as considerations when evaluating reports of these measures, such as how different approaches can make these measures appear higher or lower.
